Gastrointestinal microbiota: A predictor of COVID-19 severity?

Neag, Maria Adriana; Vulturar, Damiana-Maria; Gherman, Diana; Burlacu, Codrin-Constantin; Todea, Doina Adina

doi:10.3748/wjg.v28.i45.6328

Cited by 14 publications

(11 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COVID-19 and intestinal microbiota can interact with each other ( 39 ). Some studies suggest that intestinal microbiota may be a predictor of COVID-19 severity ( 40 , 41 ). Therefore, regulating intestinal flora seems to be an effective aspect in improving symptoms ( 42 ).…”

Section: Discussionmentioning

confidence: 99%

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundMulti system symptoms such as gastrointestinal tract and respiratory tract exist in coronavirus disease 2019 (COVID-19) patients. There is a lack of reliable evidence to prove that probiotics are effective in improving these symptoms. In this study, we aimed to evaluate the efficacy of probiotics in meta-analysis.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to February 15, 2023. Randomized controlled trials or high quality retrospective studies comparing the efficacy of probiotics as supplementation with non-probiotics in improving symptoms for patients with COVID-19 were included. This meta-analysis assessed endpoints using Review Manager 5.3.ResultTen citations comprising 1198 patients with COVID-19 were included. The results showed that probiotics could increase the number of people with overall symptom improvement (RR = 1.62, 95% CI [1.10, 2.38], P = 0.01) and shorten the duration (days) of overall symptoms (MD = −1.26, 95% CI [−2.36, −0.16], P = 0.02). For the duration (days) of specific symptoms, probiotics could improve diarrhea (MD = −2.12, 95% CI [−2.41, −1.83], P < 0.00001), cough (MD = −2.21, 95% CI [-4.56, 0.13], P = 0.06) and shortness of breath (MD = −1.37, 95% CI [-2.22, −0.53], P = 0.001). Probiotics had no obvious effect on fever, headache and weakness. For inflammation, probiotics could effectively reduce C-reactive Protein (CRP) serum level (mg/L) (MD = −4.03, 95% CI [−5.12, −2.93], P < 0.00001). Regarding hospital stay (days), probiotics group was shorter than non-probiotics group (MD = −0.98, 95% CI [−1.95, −0.01], P = 0.05).ConclusionTo some extent probiotics could improve the overall symptoms, inflammatory reaction and shorten hospital stay of patients with COVID-19. Probiotics may improve gastrointestinal symptoms (such as improving intestinal flora and reducing the duration of diarrhea) and further improve respiratory symptoms through the gut-lung axis.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=398309, identifier: CRD42023398309.

show abstract

Section: Discussionmentioning

confidence: 99%

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…17 Bacteria cause lung injury and affect intestinal function in the host, while regulating intestinal flora helps to control lung infection. 18 Schuijt et al reported that fecal transplantation through oral gavage of normal intestinal flora restored the control of lung infection and the level of cytokines in the lung in mice, demonstrating the contribution of intestinal flora to lung immunity. 19 Therefore, it was of great significance to investigate the intestinal flora of the host during pulmonary infection, and it was an important way to explore the intervention effect and mechanism of therapeutic drugs.…”

Section: Discussionmentioning

confidence: 99%

Mechanism of Qiguiyin Decoction Treats Pulmonary Infection Caused by Pseudomonas aeruginosa Based on Gut Microbiota and Metabolomics

Cui¹,

Xu²,

Hu³

et al. 2023

IDR

View full text Add to dashboard Cite

Background Qiguiyin decoction (QGYD) was a traditional Chinese medicine (TCM) used to treat Pseudomonas aeruginosa infection in China. This study investigated the therapeutic effect and the potential mechanism of QGYD on carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection. Materials and Methods Pulmonary infections were induced in mice by CRPA. The therapeutic effect of QGYD was evaluated by lung index and pulmonary pathology. The potential effects of QGYD on intestinal flora were detected by gut microbiome. The overall metabolism regulation of QGYD in blood was investigated by metabonomics. Next, the correlation between intestinal flora and metabolites was analyzed to illustrate the relationship between the regulatory effects of QGYD on metabolites and the beneficial effects of intestinal flora. Results QGYD has significant therapeutic effect on CRPA infection. QGYD profoundly inhibited the excessive accumulation of Deferribacteres and Mucispirillum at phylum and genus levels, respectively. Eleven potential metabolites that were abnormally expressed by CRPA infection and significantly reversed by QGYD were identified. Ten of the eleven metabolites significantly regulated by QGYD were related to Deferribacteres. Deferribacteres showed significant positive correlation with DL-lactic acid, phenylalanine and other metabolites and significant negative correlation with vitamin k1. At the genus level, Mucispirillum was closely related to metabolites significantly regulated by QGYD. Mucispirillum was positively correlated with metabolites such as Dl-lactate and negatively correlated with vitamin k1. Conclusion QGYD can improve CRPA infection and has the effect of regulating intestinal flora and metabolism. It was a promising drug against infection.

show abstract

“…Many proposed therapeutic approaches were introduced to target the gut microbiome, such as taking prebiotics, probiotics, and dietary modifications. During Covid19 pandemic, it was found that the gut commensals, such as Faecalibacteriumprausnitzii , Eubacterium , and Bifidobacteriumadolescentis with immunomodulatory potential suspected in COVID 19 patients, even those who were diagnosed with antibiotics (Neag et al., 2022). They were associated with increased inflammatory cytokines and blood markers of tissue damage due to microbial abundance.…”

Section: The Gut Microbiome As a Therapeutic Targetmentioning

confidence: 99%

Understanding gut microbiome‐based machine learning platforms: A review on therapeutic approaches using deep learning

Malakar,

Sutaoney,

Madhyastha

et al. 2024

Chem Biol Drug Des

View full text Add to dashboard Cite

Human beings possess trillions of microbial cells in a symbiotic relationship. This relationship benefits both partners for a long time. The gut microbiota helps in many bodily functions from harvesting energy from digested food to strengthening biochemical barriers of the gut and intestine. But the changes in microbiota composition and bacteria that can enter the gastrointestinal tract can cause infection. Several approaches like culture‐independent techniques such as high‐throughput and meta‐omics projects targeting 16S ribosomal RNA (rRNA) sequencing are popular methods to investigate the composition of the human gastrointestinal tract microbiota and taxonomically characterizing microbial communities. The microbiota conformation and diversity should be provided by whole‐genome shotgun metagenomic sequencing of site‐specific community DNA associating genome mapping, gene inventory, and metabolic remodelling and reformation, to ease the functional study of human microbiota. Preliminary examination of the therapeutic potency for dysbiosis‐associated diseases permits investigation of pharmacokinetic‐pharmacodynamic changes in microbial communities for escalation of treatment and dosage plan. Gut microbiome study is an integration of metagenomics which has influenced the field in the last two decades. And the incorporation of artificial intelligence and deep learning through “omics‐based” methods and microfluidic evaluation enhanced the capability of identification of thousands of microbes.

show abstract

Gastrointestinal microbiota: A predictor of COVID-19 severity?

Cited by 14 publications

References 157 publications

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Mechanism of Qiguiyin Decoction Treats Pulmonary Infection Caused by Pseudomonas aeruginosa Based on Gut Microbiota and Metabolomics

Understanding gut microbiome‐based machine learning platforms: A review on therapeutic approaches using deep learning

Contact Info

Product

Resources

About